NCT01282684View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Healthy

Interventions

DRUG

PLX5622

PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

DRUG

Placebo

Matching placebo for PLX5622.

Trial Locations (1)

58104

Cetero Research, Fargo